Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, announced it will host its 2026 capital markets day for investors and analysts on Tuesday, 8 September, at the London Stock Exchange. The event, themed "Maximising Sandoz Value in Its Golden Decade for Biosimilars," will run from 13:30 to 17:00 UK time and will be accessible via a live webcast. In-person attendance is by invitation only on a first-come, first-served basis, with invitations to be distributed in due course. Details for accessing the live webcast are available here.
The capital markets day comes as Sandoz celebrates 20 years of pioneering biosimilars in 2026, alongside 80 years of antibiotics manufacturing and 140 years of heritage. The company, which recorded net sales of USD 11.1 billion in 2025, operates a portfolio of approximately 1,300 medicines and reaches over one billion patients globally. The event is expected to provide insights into Sandoz's strategy to capitalize on what it calls the "golden decade for biosimilars," a period of significant patent expiries for biologic drugs that opens the door for lower-cost alternatives.
In addition to the capital markets day, Sandoz plans to host an investor and analyst site visit in Slovenia from 9-10 November. The visit will offer further insight into the company's new biosimilars development and supply-chain hub. Attendance is also by invitation only, and the event will not be webcasted. This facility underscores Sandoz's commitment to expanding its biosimilars pipeline and manufacturing capabilities, which are critical to its growth strategy.
The announcements are significant for the pharmaceutical industry and investors. Biosimilars are poised to capture a growing share of the global biologics market, which is valued at hundreds of billions of dollars. As patents for major biologic drugs expire, companies like Sandoz that can efficiently develop and manufacture biosimilars stand to benefit from increased demand for affordable treatments. For leaders in business and technology, Sandoz's focus on biosimilars highlights the intersection of pharmaceutical innovation and cost-saving technologies, including advanced manufacturing processes and supply-chain optimization.
Sandoz, headquartered in Basel, Switzerland, traces its heritage back to 1886 and employs over 20,000 colleagues of 100 nationalities. The company's purpose is "pioneering access for patients," and its leading portfolio addresses diseases from the common cold to cancer. The capital markets day and site visit will likely offer a deeper look into how Sandoz plans to maintain its leadership in a competitive market, navigate regulatory landscapes, and leverage its scale to drive growth.
Investors and analysts will be watching for details on pipeline progress, margin targets, and capital allocation priorities. The forward-looking statements in the announcement caution that actual outcomes may vary due to risks such as global economic conditions, exchange rates, and competitor activities. Nonetheless, the event reinforces Sandoz's confidence in its strategic direction and the opportunities ahead in the biosimilars space.
